Global Chimeric Antigen Receptor T (CAR-T) Cells Market, By Target Antigen (CD19, CD22, Others), Application (Acute Lymphoblastic Leukaemia, Diffuse Large B-Cell Lymphoma, Others), End-Use (Hospitals, Cancer Research Centres, Clinics) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the chimeric antigen receptor (car) t-cell treatment sector has had exceptional growth, expected to continue in the coming years. Rising investments in research and development activities, the entry of new players, product innovation, technological breakthroughs, effective resource allocation, and growing competition among business rivals to expand its regional and customer base contribute to the industry's growth.
Data Bridge Market Research analyses that the chimeric antigen receptor T (CAR-T) cells market which was USD 1,965.8 million in 2021, would rocket up to USD 28714.00 million by 2029, and is expected to undergo a CAGR of 39.82% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Target Antigen (CD19, CD22, Others), Application (Acute Lymphoblastic Leukaemia, Diffuse Large B-Cell Lymphoma, Others), End Use (Hospitals, Cancer Research Centres, Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Pfizer Inc. (U.S), Gilead Sciences, Inc. (U.S), Autolus Therapeutics (U.K), CARsgen Therapeutics Co.Ltd. (U.K), Juno Therapeutics, Inc. (U.S), Sorrento Therapeutics, Inc. (U.S), Legend Biotech (U.S), Calyxt Inc. (France), Mustang Bio (U.S), bluebird bio, Inc. (U.S), CELGENE CORPORATION (U.S), Eureka Therapeutics Inc. (U.S), Avacta Life Sciences Ltd. (U.K)
|
|
Market Opportunities
|
|
Market Definition
CAR-T therapy is a type of treatment in which a patient's T cells, which are immune cells, are genetically engineered in the lab to kill cancer cells. T cells are collected from a patient's blood. T cells in the lab are given the gene for a specific receptor that binds to a specific protein on the patient's cancer cells. Chimeric antigen receptors are a special kind of receptor (CAR). CAR-T cells are mass-produced in the lab and then injected into the patient. CAR-T therapy is used to treat certain types of blood cancers and is also being studied for use in other cancers.
Chimeric Antigen Receptor T (CAR-T) Cells Market Dynamics
Drivers
- Increasing occurrences of cancer
In the forecast period of 2022-2029, rising levels of investment for the development of advanced and technical solutions and products, an increase in the number of cell therapy clinical studies, and the growth of the pharmaceutical industry will all help to accelerate the growth of the chimeric antigen receptor T (CAR-T) cells market. In the forecast period, increasing use of cells for the treatment of various hematologic and solid tumour types would enhance numerous prospects, resulting in the expansion of the chimeric antigen receptor T (CAR-T) cells market.
- Increasing number of patients
The rise in the frequency of cancer, the increase in the number of patients who have failed to respond to alternative treatments, and the rise in healthcare costs are all predicted to promote the growth of the chimeric antigen receptor (CAR)-T cell therapy market in the forecast period.
- Increasing approvals for Car-T cell therapy products
As people become more aware of this novel way of treating cancer, demand for auto T cell therapy products rises. As a result, leading market players are working on new products, which is driving the industry forward. The US Food and Drug Administration authorized Yescarta, a cell-based gene therapy, in October 2017 to treat adult patients with certain kinds of large B-cell lymphoma. Yescarta's clearance is a breakthrough in the field of CAR-T cell treatments for cancer patients.
- Increasing R&D therapies
By 2028, the global CAR T-cell treatment industry is estimated to reach $15 billion. CAR T-cell therapy providers are likely to benefit from increased attention on research and development medicines for cancers such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer. In addition to cancer, researchers are verifying the function of therapy in a variety of other diseases, such as HIV, autoimmune disorders, infections, and others, which will drive the market's growth throughout the forecast period.
Opportunities
In addition, as people become more aware of efficiency, the market for chimeric antigen receptor (CAR)-T cell treatment is expected to develop in the coming years. However, the potential for cytokine release syndrome (CRS) and other neurological disorders as a result of cell therapy could provide further growth prospects for the chimeric antigen receptor (CAR)-T cell therapy industry in the near future.
Restraints/Challenges
In the predictable future, high treatment costs and negative effects associated with CAR T cell use would operate as a market restraint for the expansion of chimeric antigen receptor T (CAR-T) cells.
This chimeric antigen receptor T (CAR-T) cells market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chimeric antigen receptor T (CAR-T) cells market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 impact on Chimeric Antigen Receptor T (CAR-T) Cells Market
The COVID-19 epidemic has caused widespread economic and social disruption. The disease has infiltrated various sectors' value and supply chains, including the market for chimeric antigen receptor (car) t-cell treatment. The authorities implemented lockdowns in several regions. We'll look at both demand and supply to see how the COVID-19 epidemic has affected the global market. To provide a summary, the short- and long-term effects of the COVID-19 pandemic would be investigated. During and after the outbreak, this would aid in the development of business plans for all market participants, including manufacturers, vendors, suppliers, distributors, and end-users.
Recent Development
- In February 2021, After getting FDA permission for commercialization in the United States, Bristol Myers Squibb marketed Breyanzi (lisocabtagene maraleucel). Breyanzi is a cell-based gene therapy used to treat certain kinds of big B-cell lymphoma in adults.
- In July 2020, After getting FDA permission for commercialization in the United States, Kite Pharma, a Gilead Sciences subsidiary, introduced Tecartus. Tecartus (brexucabtagene autoleucel, formerly KTE-X19) is the first and only CAR T-cell therapy licenced for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Global Chimeric Antigen Receptor T (CAR-T) Cells Market Scope
The chimeric antigen receptor T (CAR-T) cells market is segmented on the basis of target antigen, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Target Antigen
- CD19
- CD22
- Others
Application
- Acute Lymphoblastic Leukaemia
- Diffuse Large B-Cell Lymphoma
- Others
End User
- Hospitals
- Cancer Research Centres
- Clinics
Chimeric Antigen Receptor T (CAR-T) Cells Market Regional Analysis/Insights
The chimeric antigen receptor T (CAR-T) cells market is analysed and market size insights and trends are provided by country, target antigen, application and end-user as referenced above.
The countries covered in the chimeric antigen receptor T (CAR-T) cells market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominating the chimeric antigen receptor T (CAR-T) cells market due to the high prevalence of cancer.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the prevalence of better healthcare infrastructure along with growing disposable income of the people.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Chimeric Antigen Receptor T (CAR-T) Cells Market Share Analysis
The chimeric antigen receptor T (CAR-T) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chimeric antigen receptor T (CAR-T) cells market.
Some of the major players operating in the chimeric antigen receptor T (CAR-T) cells market are:
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S)
- Gilead Sciences, Inc. (U.S)
- Autolus Therapeutics (U.K)
- CARsgen Therapeutics Co. Ltd. (U.K)
- Juno Therapeutics, Inc.(U.S)
- Sorrento Therapeutics, Inc. (U.S)
- Legend Biotech (U.S)
- Calyxt Inc. (France)
- Mustang Bio (U.S)
- bluebird bio, Inc. (U.S)
- CELGENE CORPORATION (U.S)
- Eureka Therapeutics Inc. (U.S)
- Avacta Life Sciences Ltd. (U.K)
SKU-